Postoperative Insulin Intervention After Pancreatectomy in nDM Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Insulin Infusion, No Insulin Infusion (Standard Monitoring Only).
- Who it may be relevant to
- Registry conditions: Postoperative Hyperglycemia, Pancreatectomy. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Insulin Intervention After Pancreatectomy in Preoperative Non-diabetic Patients : Randomized Non-inferiority Clinical Trial
Overview
The goal of this randomized non-inferiority clinical trial is to evaluate whether routine postoperative insulin infusion can be safely omitted in preoperative non-diabetic adult patients undergoing pancreatectomy for periampullary or pancreatic tumors. The primary purpose is to determine whether withholding insulin infusion provides comparable glycemic control while reducing treatment-related burden and adverse events. The main questions it aims to answer are: * Does omission of postoperative insulin infusion result in non-inferior mean blood glucose levels through postoperative day (POD) 3 compared to standard insulin infusion? * Does omission of insulin infusion reduce the incidence of hypoglycemia without increasing postoperative complications, including surgical site infection within 3 months? Researchers will compare a no-insulin infusion group (intervention arm) with a standard insulin infusion group (control arm) to determine whether avoiding routine insulin infusion maintains comparable glycemic control while improving safety and patient comfort. Participants will: * Undergo pancreatectomy and be randomly assigned (1:1) to either receive standard insulin infusion or no routine insulin infusion postoperatively * Have blood glucose monitored using intermittent testing and continuous glucose monitoring (flash glucose monitoring system) * Receive protocol-based glycemic management, including rescue insulin if hyperglycemia occurs or discontinuation if hypoglycemia develops * Be followed for up to 3 months postoperatively to assess glycemic outcomes, hypoglycemic events, surgical site infection, and other postoperative complications * Complete a questionnaire assessing discomfort related to glucose monitoring and insulin administration This study aims to establish evidence-based postoperative glucose management strategies for non-diabetic patients undergoing pancreatectomy.
Interventions
- Drug Insulin Infusion
Continuous intravenous insulin infusion administered postoperatively according to institutional protocol. Blood glucose levels are monitored at regular intervals, and the infusion rate is adjusted to maintain target glucose levels (typically 140-180 mg/dL). Insulin infusion is continued until postoperative day 2 (9 AM) unless discontinued earlier due to hypoglycemia or clinical indication. - Other No Insulin Infusion (Standard Monitoring Only)
Postoperative management without routine insulin infusion. Blood glucose levels are monitored four times daily. If fasting blood glucose exceeds 180 mg/dL for two consecutive days, rescue insulin therapy is initiated according to institutional protocol. All other perioperative care follows standard postoperative management.
Primary outcome measures
- Mean Blood Glucose Level (Average of Daily Mean Values from Postoperative Day 0 to 3) [Time frame: From postoperative day 0 through postoperative day 3]
Secondary outcome measures (7)
- Mean Blood Glucose Level on Postoperative Day 0 [Time frame: Postoperative day 0]
- Mean Blood Glucose Level on Postoperative Day 1 [Time frame: Postoperative day 1]
- Mean Blood Glucose Level on Postoperative Day 2 [Time frame: Postoperative day 2]
- Mean Blood Glucose Level on Postoperative Day 3 [Time frame: Postoperative day 3]
- Postoperative Blood Glucose Variability [Time frame: From postoperative day 0 through postoperative day 3]
- Incidence of Hypoglycemia [Time frame: From postoperative day 0 through postoperative day 3]
- Incidence of Surgical Site Infection (SSI) [Time frame: Within 3 months after surgery]
Eligibility criteria
Inclusion criteria
- Adults aged 18 to 80 years
- Patients without a prior diagnosis of diabetes mellitus
- Patients scheduled to undergo pancreatectomy for periampullary tumors or pancreatic tumors
- Ability to understand the study and provide written informed consent
Exclusion criteria
- Patients diagnosed with pancreatic adenocarcinoma
- Patients undergoing total pancreatectomy
- Patients undergoing hepatopancreatoduodenectomy (HPD) or with a history of prior hepatectomy
- Patients with severe comorbidities (e.g., liver cirrhosis, chronic kidney disease, or heart failure)
- Patients currently enrolled in another clinical trial that may interfere with this study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
South Korea · 1 center
- Asan medical center — Seoul
Identifiers
NCT: NCT07540975 · 2021-1708